--- title: "GeoVax Labs files NT 10-K, says 2025 annual report will be late" url: "https://aibio.space/news/geovax-labs-files-nt-10-k-says-2025-annual-report-will-late/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-03-31" section: "Distress" tickers: "NASDAQ:GOVX" source: "https://www.sec.gov/Archives/edgar/data/832489/000143774926010722/govx20260330_nt10k.htm" summary: "GeoVax missed the March 31, 2026 deadline for its 2025 annual report and expects to file within 15 days. It expects a 2025 net loss of about $21.5 million," --- By the aibio.space news desk. Sources - [GeoVax Labs, Inc. Form NT 10-K filed March 31, 2026 (SEC EDGAR)](https://www.sec.gov/Archives/edgar/data/832489/000143774926010722/govx20260330_nt10k.htm) - [GeoVax Labs, Inc. Form 10-K filed March 27, 2025: business overview and signatures (SEC EDGAR)](https://www.sec.gov/Archives/edgar/data/832489/000143774925009614/govx20241231_10k.htm) [GOVX](https://aibio.space/companies/geovax-labs/) 2026-03-31 # GeoVax Labs files NT 10-K, says 2025 annual report will be late Tickers [GOVX](https://aibio.space/companies/geovax-labs/) GeoVax missed the March 31, 2026 deadline for its 2025 annual report and expects to file within 15 days. It expects a 2025 net loss of about $21.5 million, and its 2024 annual report carried a going-concern warning from the auditors. ## Key facts - **Company**: GeoVax Labs, Inc. (NASDAQ: GOVX) - **News type**: Distress - **Primary source**: [GeoVax Labs, Inc. Form NT 10-K filed March 31, 2026 (SEC EDGAR)](https://www.sec.gov/Archives/edgar/data/832489/000143774926010722/govx20260330_nt10k.htm) *Old law books on library shelves. CC0, via rawpixel. The picture shows the field, not the companies named.* GeoVax Labs, Inc. (Nasdaq: [GOVX](https://aibio.space/companies/geovax-labs/)) said on March 31, 2026 that it cannot file its annual report on Form 10-K for the year ended December 31, 2025 by the March 31, 2026 due date. The company filed a [Form NT 10-K](https://www.sec.gov/Archives/edgar/data/832489/000143774926010722/govx20260330_nt10k.htm), a notice of late filing, and says it expects to file within the 15-calendar-day extension that Rule 12b-25 allows. ## Why the report is late GeoVax says it determined it could not file the 10-K by the original due date without unreasonable effort or expense. The reason it gives is delays in compiling and reviewing certain information for the report. The notice is signed by Mark W. Reynolds, the chief financial officer, who is also named as the contact person. The notice answers yes to the question of whether all other periodic reports required over the preceding 12 months have been filed. The notice does not say whether the auditors have finished their work or whether any restatement is involved. ## The 2025 loss and the 2024 position The notice says GeoVax anticipates a net loss of approximately $21.5 million for the year ended December 31, 2025. It compares that with a net loss of $25 million for 2024. The notice gives no 2025 year-end cash, working capital or financing figures. The company's 2024 annual report, filed March 27, 2025, shows cash and cash equivalents of $5,506,941 at December 31, 2024, down from $6,452,589 a year earlier. Working capital was $4,827,551 at the end of 2024, compared with $4,365,861 at the end of 2023. Net cash used in operating activities was $24,675,511 in 2024, against $25,173,639 in 2023. Financing activities provided $23,750,516 in 2024. The same report contains an emphasis-of-matter paragraph from its independent registered public accounting firm. The auditors said the company expects to keep generating operating losses and will need more funding for its research and development. They said this raises substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from that uncertainty. The annual report also says GeoVax plans to seek non-dilutive capital through government grant programs and clinical trial support. It adds that the company may offer more equity securities, debt or convertible debt instruments. New equity offerings would dilute existing holders, and the report does not size any such raise. ## Programs and what the company says comes next GeoVax describes itself as a clinical-stage company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers. In that report, its lead clinical program was GEO-CM04S1, a next-generation COVID-19 vaccine. The annual report says the company had been awarded a BARDA-funded contract to sponsor a randomized Phase 2b trial of 10,000 participants comparing GEO-CM04S1 with an FDA-approved COVID-19 vaccine. The company had expected that trial to start in the second half of 2025. The notice does not address the trial's status. In oncology, the company describes Gedeptin, an oncolytic solid tumor gene-directed therapy. It completed a multicenter Phase 1/2 trial in advanced head and neck cancers, and the FDA has granted it orphan drug status for certain oral and pharyngeal cancers. GeoVax also describes GEO-MVA, a vaccine targeting Mpox and smallpox, with clinical evaluation expected to begin in 2025. The report counts more than 135 granted or pending patent applications across 23 patent families. The next step the company names is the 10-K itself, which it expects to file within 15 calendar days after March 31, 2026. The annual report also says the company will require substantial additional financing at various intervals to fund its operations, including its clinical trials. As of the notice, the audited 2025 figures had not been filed. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story GOVX GeoVax Labs, Inc. NASDAQ ยท United States Open the starter desk ## More in Distress Distress ### [Mineralys takes ownership of lorundrostat patents but keeps Tanabe milestone debts](https://aibio.space/news/mineralys-takes-ownership-lorundrostat-patents-but-keeps-tanabe/) Oct 29, 2026 Distress ### [Bristol Myers Squibb drops Prothena's PRX019, ending up to $617.5 million in milestones](https://aibio.space/news/bristol-myers-squibb-drops-prothenas-prx019-ending-up-617-5-million/) Oct 29, 2026 Distress ### [LENZ Therapeutics reorganizes to cut 2027 operating expenses by more than 50%](https://aibio.space/news/lenz-therapeutics-reorganizes-cut-2027-operating-expenses-more-50/) Oct 28, 2026 --- Source page: https://aibio.space/news/geovax-labs-files-nt-10-k-says-2025-annual-report-will-late/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "GeoVax Labs files NT 10-K, says 2025 annual report will be late", 2026-03-31, https://aibio.space/news/geovax-labs-files-nt-10-k-says-2025-annual-report-will-late/